This company engineers the chemical building blocks necessary for developing advanced RNA therapies. They redefine nucleoside synthesis by applying small molecule drug discovery principles to create precisely tailored, scalable nucleosides. This expanded chemical toolkit enables the creation of smarter RNA therapeutics to treat rare and undruggable diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Developing effective RNA therapies is challenging due to limitations in the chemical diversity of available nucleoside building blocks. This restricts the ability to fine-tune drug properties and target previously "undruggable" diseases. Current nucleoside synthesis methods lack the scalability and precision needed for next-generation RNA therapeutics.
Solution
Cloudburst Biotech is developing a library of structurally tailored nucleoside analogs designed to improve the efficacy and safety of RNA therapies. By applying principles from small molecule drug discovery to nucleoside synthesis, Cloudburst is expanding the chemical space available for oligonucleotide therapeutics. This approach enables the creation of RNA medicines with precisely tuned properties, allowing them to target disease at its genetic roots and address critical unmet needs in treating rare and undruggable diseases. The company's platform aims to deliver personalized medicine by providing the building blocks for smarter RNA therapies.
Target Audience
Cloudburst Biotech's primary customers are pharmaceutical companies and research institutions developing RNA-based therapeutics, particularly those focused on antisense oligonucleotides and other modalities for treating genetic diseases.
Features
- Expanding library of structurally diverse nucleoside analogs
- Scalable synthesis methods for producing tailored nucleosides
- Application of chemical space principles to oligonucleotide therapeutics
- Focus on improving the safety and efficacy profiles of RNA medicines
- Targeting of previously undruggable or rare diseases